CA2530655A1 - Passive immune therapy against malignant melanoma - Google Patents

Passive immune therapy against malignant melanoma Download PDF

Info

Publication number
CA2530655A1
CA2530655A1 CA002530655A CA2530655A CA2530655A1 CA 2530655 A1 CA2530655 A1 CA 2530655A1 CA 002530655 A CA002530655 A CA 002530655A CA 2530655 A CA2530655 A CA 2530655A CA 2530655 A1 CA2530655 A1 CA 2530655A1
Authority
CA
Canada
Prior art keywords
malignant melanoma
therapy against
immune therapy
against malignant
passive immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002530655A
Other languages
French (fr)
Inventor
Ursula Wiedermann
Soldano Ferrone
Hubert Pehamberger
Otto Scheiner
Erika Jensen-Harolim
Christoph Zielinski
Heimo Breiteneder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolife Science Forschungs und Entwicklungs GmbH
Original Assignee
Biolife Science Forschungs-Und Entwicklungsgesellschaft M.B.H.
Ursula Wiedermann
Soldano Ferrone
Hubert Pehamberger
Otto Scheiner
Erika Jensen-Harolim
Christoph Zielinski
Heimo Breiteneder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolife Science Forschungs-Und Entwicklungsgesellschaft M.B.H., Ursula Wiedermann, Soldano Ferrone, Hubert Pehamberger, Otto Scheiner, Erika Jensen-Harolim, Christoph Zielinski, Heimo Breiteneder filed Critical Biolife Science Forschungs-Und Entwicklungsgesellschaft M.B.H.
Publication of CA2530655A1 publication Critical patent/CA2530655A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is the use of antibodies for producing an immunizing vaccine against HMW-MAA on melanomas.

Claims
CA002530655A 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma Abandoned CA2530655A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10328121.5 2003-06-23
DE10328121A DE10328121A1 (en) 2003-06-23 2003-06-23 Passive immunotherapy for malignant melanoma
PCT/EP2004/006519 WO2005000349A2 (en) 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma

Publications (1)

Publication Number Publication Date
CA2530655A1 true CA2530655A1 (en) 2005-01-06

Family

ID=33546608

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002530655A Abandoned CA2530655A1 (en) 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma

Country Status (6)

Country Link
EP (1) EP1638604A2 (en)
AU (1) AU2004251010A1 (en)
CA (1) CA2530655A1 (en)
DE (1) DE10328121A1 (en)
IL (1) IL172751A0 (en)
WO (1) WO2005000349A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101146909A (en) * 2005-03-25 2008-03-19 格黎卡特生物技术股份公司 Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (en) * 1981-09-08 1983-03-14 Suntory Ltd Selective carcinostatic agent
USH819H (en) * 1984-04-30 1990-09-04 The United States Of America As Represented By The Secretary Of Energy Palladium-109 labeled anti-melanoma monoclonal antibodies
EP0380607B1 (en) * 1988-05-17 1994-12-14 FERRONE, Soldano Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen
WO1994021294A1 (en) * 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
SE9902989D0 (en) * 1999-08-24 1999-08-24 Active Biotech Ab Novel compounds

Also Published As

Publication number Publication date
WO2005000349A3 (en) 2005-05-06
WO2005000349A2 (en) 2005-01-06
DE10328121A1 (en) 2005-02-03
IL172751A0 (en) 2006-04-10
EP1638604A2 (en) 2006-03-29
AU2004251010A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
AU2002327338A1 (en) Use of glycosylceramides as adjuvants for vaccines against infections and cancer
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
DE60237307D1 (en) ADJUSTABLE HEART RESYNCHRONIZATION
IS6964A (en) Immunotherapy formulations for the treatment of tumors that often ganglioside
WO2002080648A3 (en) Mucosal boosting following parenteral priming
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004053086A3 (en) Plasmodium falciparum antigens and methods of use
AU2003258081A1 (en) Cancer vaccines containing epitopes of oncofetal antigen
AU2002349543A1 (en) Tumor antigens
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
PL356770A1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
CA2530655A1 (en) Passive immune therapy against malignant melanoma
NO20024255L (en) HIV Immune Adjuvant Therapy
MXPA03006412A (en) Methods of administering epothilone analogs for the treatment of cancer.
WO2004106379A8 (en) Immunotherapy of rectal cancer
EP1642876A4 (en) Aluminum nitride conjugate body and method of producing the same
AU2002304883A1 (en) Device for the treatment of tumours
EP1454914A4 (en) Tumor antigen
AU2003268180A1 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2006070432A3 (en) Anti-tumoral immunogenic peptides and vaccine thereof
AU2002304717A1 (en) Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
AU2002354738A1 (en) Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued